Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q3 2024
Institutional positions in Recursion Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 268
- +1 vs. Q2 2024
- Shares held
- 264.5M
- +30.2M (+12.9%) vs. Q2 2024
- Total value
- $1.74B
- −$13.9M (−0.8%) vs. Q2 2024
- New holders
- 45
- 112 more added
- Sold out
- 44
- 52 more reduced
3 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RXRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 344 | $1.33B |
| Q1 2026 | 335 | $1.03B |
| Q4 2025 | 335 | $1.33B |
| Q3 2025 | 322 | $1.58B |
| Q2 2025 | 333 | $1.57B |
| Q1 2025 | 337 | $1.63B |
| Q4 2024 | 316 | $2.06B |
| Q3 2024 | 268 | $1.74B |
| Q2 2024 | 270 | $1.89B |
| Q1 2024 | 248 | $2.12B |
| Q4 2023 | 199 | $2.04B |
| Q3 2023 | 192 | $1.16B |
| Q2 2023 | 158 | $952.8M |
| Q1 2023 | 159 | $841.4M |
| Q4 2022 | 144 | $954.0M |
| Q3 2022 | 146 | $1.21B |
| Q2 2022 | 133 | $861.1M |
| Q1 2022 | 128 | $680.3M |
| Q4 2021 | 126 | $1.62B |
| Q3 2021 | 84 | $1.26B |
| Q2 2021 | 75 | $1.71B |
| Q1 2021 | 1 | $1.00K |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Recursion Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Healthcare of Ontario Pension Plan Trust Fund | 0 | $0 | 0.00% | −1,366−100.0% | Sold out |
| Sandia Investment Management LP | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −394−100.0% | Sold out |
| Continuum Advisory, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Innealta Capital, LLC | 0 | $0 | 0.00% | −221−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Triad Wealth Partners, LLC | 0 | $0 | 0.00% | −153−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −138−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −81−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Gradient Investments LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Hazlett, Burt & Watson, Inc. | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Benjamin F. Edwards & Company, Inc. | – | – | – | – | Not filed |
| Hoylecohen, LLC | – | – | – | – | Not filed |